<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="826">
  <stage>Registered</stage>
  <submitdate>11/09/2005</submitdate>
  <approvaldate>11/09/2005</approvaldate>
  <nctid>NCT00192595</nctid>
  <trial_identification>
    <studytitle>Tenofovir in HIV/HBV Coinfection</studytitle>
    <scientifictitle>Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral naïve Patients With HIV/HBV Co-infection</scientifictitle>
    <utrn />
    <trialacronym>TICO</trialacronym>
    <secondaryid>TICO</secondaryid>
    <secondaryid>VHWG001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infection</healthcondition>
    <healthcondition>Hepatitis B Coinfection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tenofovir
Treatment: drugs - Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)

Active Comparator: Arm 1: - Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)

Experimental: Arm 2 - Zidovudine (AZT), tenofovir (TDF), efavirenz (EFV)

Experimental: Amr 3 - Lamivudine (LAM), tenofovir (TDF), efavirenz (EFV)


Treatment: drugs: Tenofovir


Treatment: drugs: Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare HBV DNA suppression to levels below the limit of detection (&lt;400 copies/ml) by week 48 in each group</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>-HBV resistance at 48 weeks; -undetectable HBV DNA at weeks 12 &amp; 24; -HBeAg and HBsAg seroconversion at weeks 24 &amp; 48; -ALT chnages and rate of hepatic cytolysis; -HIV-1 RNA supression and CD4/CD8 changes over 48 weeks;</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent

          -  Documented HIV infection (positive serology for HIV-1 and detectable HIV-1 RNA)

          -  Age 18 - 70 years

          -  HBV DNA &gt; 105 copies/ml

          -  HBsAg positive &gt;6 months or HBsAg positive and anti HB core IgM negative

          -  Creatinine &lt;= 2.0mg/dl (&lt;= 0.2 mmol/L)

          -  Platelet count &gt;= 50,000/mm

          -  HIV-1 antiretroviral therapy naïve

          -  No prior exposure to anti-HBV agents (LAM, adefovir, TDF) although prior IFN treatment
             allowed</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  HCV-RNA positive or Anti-HAV IgM positive

          -  Acute hepatitis (serum ALT &gt; 1000 U/L)

          -  Active opportunistic infection

          -  Other causes of chronic liver disease identified (autoimmune hepatitis,
             hemochromatosis, Wilsons disease, alfa-1-antitrypsin deficiency)

          -  Concurrent malignancy requiring cytotoxic chemotherapy

          -  Decompensated or Child's C cirrhosis

          -  Alfa-fetoprotein (AFP) &gt; 3X ULN (unless negative CT scan or MRI within 3 months of
             entry date)

          -  Pregnancy or lactation

          -  Any other condition which in the opinion of the investigator might interfere with
             compliance or outcome of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>36</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>St. Vincent's Hospital - Darlinghurst</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The University of New South Wales</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Gilead Sciences</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to compare the effectiveness of 3 different treatment regimens in
      reducing or clearing the Hepatitis B Virus in patients infected with HIV and Hepatitis B
      (co-infection)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00192595</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Greg Dore, MBBS, FRACP</name>
      <address>National Centre in HIV Epidemiology and Clinical Research.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>